Dynavax Technologies Corporation
http://www.dynavax.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dynavax Technologies Corporation
Asia Deal Watch: Bone Therapeutics Licenses Bone Cell Therapy Tech To Two Asian Firms
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
Belgium's Argenx Advances On More Positive Efgartigimod Data
Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.
Legal Notebook: Catalyst’s Suit vs. FDA Is Tossed, Avonex Patent Invalidity Verdict Is Reinstated
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Symphony Dynamo, Inc. (SDI)